New Guidance on Conflict of Interest Disclosures for Advisory Committees

The US Food and Drug Administration (FDA) released new draft guidance on 8 March about the availability of conflict of interest information and waiver information for members of advisory committees.

The guidance also establishes a procedure for disclosing financial interest and granting conflict-of-interest (COI) waivers to special Government employees (SGEs) and regular employees. The guidance also provides a standardized mechanism for public disclosure of such documents.

Read more:

FDA - Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers

Federal Register - Guidance for the Public, Advisory Committee Members, and Staff; Availability: Advisory Committee Members' Financial Interest Information and Waivers